A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : AR-V7

Search Conditions:
Search Keyword : AR-V7
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: AR-V7
Appearance Frequency: 167 time(s)
Long forms: 8

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
androgen receptor splice variant 7
(94 times)
Neoplasms
(30 times)
CRPC (33 times)
mCRPC (27 times)
CTCs (21 times)
2014 [Impact of AR-V7 expression on overall survival for patients with metastatic prostate cancer].
AR splice variant 7
(29 times)
Neoplasms
(11 times)
AR (26 times)
CRPC (10 times)
PCa (8 times)
2014 Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
androgen receptor variant 7
(26 times)
Neoplasms
(5 times)
CTCs (8 times)
CRPC (7 times)
PCa (7 times)
2016 CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
AR variant 7
(14 times)
Neoplasms
(6 times)
AR (12 times)
CRPC (3 times)
5ARI (2 times)
2015 NF-kappaB and androgen receptor variant expression correlate with human BPH progression.
androgen receptor such as the V7 splice variant
(1 time)
Cell Transformation, Neoplastic
(1 time)
CRPC (1 time)
2018 LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
androgen-receptor splice variant 7 messenger RNA
(1 time)
Medicine
(1 time)
PSA (1 time)
2014 AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
AR and the mutants especially the splice variant 7
(1 time)
Chemistry
(1 time)
AR (1 time)
AR-full (1 time)
LBD (1 time)
2019 Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
variant 7
(1 time)
Clinical Medicine
(1 time)
AR (1 time)
BRD4 (1 time)
CRPC (1 time)
2021 Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.